Abstract 46P
Background
Lenvatinib has been identified as a multikinase inhibitor with the effect of inhibiting angiogenesis for advanced ICC. This study aimed to compare the efficacy and safety of GEMOX and PD-1 inhibitors combined with or without lenvatinib as first-line therapy for advanced ICC.
Methods
Eligible participants with treatment naive and diagnosis of unresectable advanced ICC were assigned to G-P-L group: gemcitabine (1000 mg/m2on days 1 and 8 every 3 weeks), oxaliplatin (85 mg/m2on day 1 every 3 weeks), PD-1 inhibitors and lenvatinib (12 mg for weight ≥ 60 kg or 8 mg for weight < 60 kg, once daily), and G-P group: gemcitabine, oxaliplatin and PD-1 inhibitors. The primary endpoints was to assess objective response rate (ORR) evaluated with mRECIST 1.1 and adverse events (AEs). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Genetic mutation biomarkers for lenvatinib were explored using WES.
Results
77 patients were enrolled and divided into G-P-L group (n=38) and G-P group (n=39). The median follow-up time was 23 months. The median PFS were 13 months in the G-P-L group and 7.9 months in the G-P group (hazard ratio[HR]: 0.38, 95% CI: 0.20–0.71, P=0.007). The median OS were 18.5 months in the G-P-L group and 14.6 months in the G-P group (P=0.19). No significant differences of grade ≥ 3 AEs were found between the G-P-L group and the G-P group (68.4% and 64.1%). ORR, DCR were 39.5% and 89.5% in the G-P-L group versus 33.3% and 76.9% in the G-P group, respectively. Multivariate Cox regression analysis indicated that with or without Lenvatinib combination was the independent risk factor of PFS in the entire group (P=0.002). Keap-1 gene mutation was found with significant difference in PR group comparing with SD and PD group in the G-P-L group (P=0.003).
Conclusions
GEMOX combined with PD-1 inhibitor and lenvatinib indicated the feasibility as first-line therapy for advanced ICC with Keap-1 gene mutation. Multi-center with large scale of cases study were needed for further exploration.
Clinical trial identification
NCT05215665.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
246P - Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Presenter: Anna C. Weiss
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
248P - Impact of unilateral mastectomy with or without immediate breast reconstruction on vertebral alignment
Presenter: Jong-Ho Cheun
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13